Literature DB >> 16952214

First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.

K Spencer1, N J Cowans, K Avgidou, K H Nicolaides.   

Abstract

OBJECTIVES: To examine the clinical utility of the first-trimester markers of aneuploidy in their ability to predict future fetal loss.
METHODS: We examined 54,722 singleton pregnancies with no chromosomal abnormality and with complete outcome data that had undergone screening for trisomy 21 by a combination of fetal nuchal translucency (NT) thickness, maternal serum free beta-human chorionic gonadotropin (beta-hCG) and pregnancy-associated plasma protein-A (PAPP-A) at 11 + 0 and 13 + 6 weeks' gestation. The biochemical markers were converted to multiples of the expected normal median for a pregnancy of the same gestation (MoM) and the measurements of fetal NT were expressed as the difference (delta) from the normal median NT for crown-rump length (CRL). The association between free beta-hCG, PAPP-A and delta NT and the incidence of fetal loss prior to 24 weeks, at or after 24 weeks or at any time, was assessed by comparing the relative incidence at a number of MoM or delta NT cut-offs and at various centile cut-offs. At various marker levels the likelihood ratio (LR) for fetal loss was also calculated.
RESULTS: The rate of fetal loss increased with decreasing maternal serum free beta-hCG and PAPP-A and increasing delta NT. At the 5th centile of the normal outcome group for free beta-hCG (0.41 MoM) the odds ratio for fetal loss before 24 weeks, at or above 24 weeks and at any gestation was 3.1, 1.8 and 2.6, respectively. The respective values for the 5th centile of PAPP-A (0.415 MoM) were 3.3, 1.9 and 2.8 and for the 95th centile of delta NT they were 2.5, 1.9 and 2.2, respectively. There was almost no correlation between reduced levels (<or=0.50 MoM) of PAPP-A and reduced levels of free beta-hCG in either the normal pregnancy group (r = 0.041) or the group with fetal death (r = 0.072), indicating relatively independent prediction by either biochemical marker.
CONCLUSIONS: Low levels of maternal serum PAPP-A and free beta-hCG and increased fetal NT are associated, in the absence of an abnormal karyotype, with an increased risk of impending fetal death. The likelihood ratio profiles provided at various levels of PAPP-A or free beta-hCG may be of some help in counseling women with such results and raise awareness among health-care professionals for increased surveillance in such cases. Copyright 2006 ISUOG. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16952214     DOI: 10.1002/uog.3809

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  11 in total

1.  Management of abnormal serum markers in the absence of aneuploidy or neural tube defects.

Authors:  William T Schnettler; Michele R Hacker; Rachel E Barber; Sarosh Rana
Journal:  J Matern Fetal Neonatal Med       Date:  2012-03-26

2.  Variation of papp-a level in the first trimester of pregnancy and its clinical outcome.

Authors:  Mithil Patil; T M Panchanadikar; Girija Wagh
Journal:  J Obstet Gynaecol India       Date:  2013-12-01

Review 3.  Predictive value of pregnancy-associated plasma protein-A in relation to fetal loss: A systematic review and meta-analysis.

Authors:  Zahra Hadizadeh-Talasaz; Ali Taghipour; Seyede Houra Mousavi-Vahed; Robab Latifnejad Roudsari
Journal:  Int J Reprod Biomed       Date:  2020-06-30

4.  Prediction of Preeclampsia by First Trimester Combined Test and Simple Complete Blood Count Parameters.

Authors:  Ayse Kirbas; Ali Ozgur Ersoy; Korkut Daglar; Turkan Dikici; Ebru Hacer Biberoglu; Ozgur Kirbas; Nuri Danisman
Journal:  J Clin Diagn Res       Date:  2015-11-01

5.  Placental hCG immunohistochemistry and serum free-Beta-hCG at 11-13 weeks' gestation in intrauterine fetal demise.

Authors:  Ambrogio P Londero; Maria Orsaria; Tiziana Grassi; Angelo Calcagno; Stefania Marzinotto; Maria Ceraudo; Arrigo Fruscalzo; Lorenza Driul; Laura Mariuzzi
Journal:  Histochem Cell Biol       Date:  2012-11-21       Impact factor: 4.304

6.  Record linkage to obtain birth outcomes for the evaluation of screening biomarkers in pregnancy: a feasibility study.

Authors:  Samantha J Lain; Charles S Algert; Vitomir Tasevski; Jonathan M Morris; Christine L Roberts
Journal:  BMC Med Res Methodol       Date:  2009-07-09       Impact factor: 4.615

Review 7.  Maternal Serum Screening Markers and Adverse Outcome: A New Perspective.

Authors:  David Krantz; Terrence Hallahan; David Janik; Jonathan Carmichael
Journal:  J Clin Med       Date:  2014-07-03       Impact factor: 4.241

8.  Abnormal analyte preeclampsia: do the second-trimester maternal serum analytes help differentiate preeclampsia subtypes?

Authors:  A S Critchfield; J K Paulus; R Farez; A C Urato
Journal:  J Perinatol       Date:  2013-05-23       Impact factor: 2.521

9.  First trimester screening using ultrasound and serum markers in Panamanians: Factors associated with adverse pregnancy outcomes.

Authors:  Tania T Herrera; Scarlett Sinisterra; Alcibiades Solis; Gabrielle B Britton
Journal:  J Res Med Sci       Date:  2014-05       Impact factor: 1.852

10.  New approach for estimating risk of miscarriage after chorionic villus sampling.

Authors:  M M Gil; F S Molina; M Rodríguez-Fernández; J L Delgado; M P Carrillo; J Jani; W Plasencia; V Stratieva; N Maíz; P Carretero; A Lismonde; P Chaveeva; J Burgos; B Santacruz; J Zamora; C De Paco Matallana
Journal:  Ultrasound Obstet Gynecol       Date:  2020-10-17       Impact factor: 7.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.